References
Bauernfind A, Sauerwein D, Danniger J, Keding M: Reduktion der Empfindlichkeit vonPseudomonas aeruginosa gegenüber neuen 4-Quinolonen durch Mutation in Vitro und in Vivo. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie 1984, 3: 521–529.
Limb DI, Dabbs DJW, Spancer RC: In vitro selection of bacteria resistant to the 4-quinolone agents. Journal of Antimicrobial Chemotherapy 1987, 19: 65–71.
Desplaces N, Gutman L, Carlet J, Guibert J, Acar JF: The new quinolones and their combinations with other agents for therapy of severe infections. Journal of Antimicrobial Chemotherapy 1986, 17; Supplement A: 25–39.
Bairley RR, Peddie BA, Blake E: Norfloxacin for the treatment of uncomplicated urinary tract infections. New Zealand Medical Journal 1983, 96: 476.
Sato K, Inone Y, Fujii T, Aoyama H, Inone M, Mitsuhashi M: Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrobial Agents and Chemotherapy 1986, 30: 777–780.
Aoyama H, Sato K, Kato K, Hirai K, Mitsuhashi S: Norfloxacin resistance in a clinical isolate ofEscherichia coli. Antimicrobial Agents and Chemotherapy 1987, 31: 1640–1641.
Lewin CS, Smith JT, Hamilton-Miller JMT, Brumfitt W: Gain of antibioticsenstivity accompanying emergence of clinical ciprofloxacin resistance. Lancet 1988, i: 1462–1463.
Aubert G, Puech C, Lucht F, Loboguerrero M, Denis M, Dorche G: Activité de cinq fluoroquinolones sur les bacilles à gram négatif hospitaliers de différentes sensibilités à la péfloxacine. Pathologie Biologie 1989, 8: 881–887.
Lopez-Brea M, Alarcón T: Isolation of fluoroquinolone-resistantEscherichia coli andKlebsiella pneumonia from an infected Hickman catheter. European Journal of Clinical Microbiology and Infectious Diseases 1990, 9: 345–346.
Watanabe M, Kotera Y, Yosue K, Inoue M, Mitsuhashi S: In vitro emergence of quinolone-resistant mutants ofEscherichia coli, Enterobacter cloacae, andSerratia marcescens. Antimicrobial Agents and Chemotherapy 1990, 34: 173–175.
Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EEC, Cullen ME: Ciprofloxacin and fluoroquinolones. American Journal of Medicine 1989, 87, Supplement 5A: 8.
Cullen ME, Wyke AW, Kuroda R, Fisher LM: Cloning and characterization of a DNA gyrase A gene fromEscherichia coli that confers clinical resistance to 4-quinolones. Antimicrobial Agents and Chemotherapy 1989, 33: 886–894.
Hooper DC, Wolfson JS, Sonza KS, Tung C, McHugh GL, Skartz MN: Genetic and biochemical characterization of norfloxacin resistance inEscherichia coli. Antimicrobial Agents and Chemotherapy 1986, 29: 639–644.
Hirai K, Aoyama H, Suzue S, Irikura T, Iyobe S, Mitsuhashi S: Isolation and characterization of norfloxacin-resistant mutants ofEscherichia coli K-12. Antimicrobial Agents and Chemotherapy 1986, 30: 248–253.
Cohen SP, McMurray LM, Hooper DC, Wolfson JS, Levy SB: Cross-resistance to fluoroquinolones in multipleantibiotic-resistant (MAR)Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrobial Agents and Chemotherapy 1989, 33: 1318–1325.
Ronald AR, Turck M, Petersdorf RG: A critical evaluation of nalidixic acid in urinary tract infections. New England Journal of Medicine 1966, 175: 1081–1089.
Lumish RM, Norden CW: Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid. Antimicrobial Agents and Chemotherapy 1975, 7: 159–163.
Jonsson M, Englund G, Nörgård K: Norfloxacin versus pivmecillinam in the treatment of uncomplicated lower urinary tract infection in hospitalized elderly patients. Scandinavian Journal of Infectious Diseases 1990, 22: 339–344.
Greenwood D, Osman M, Goodwin J, Cowishaw WA, Slack R: Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance. Journal of Antimicrobial Agents and Chemotherapy 1984, 13: 315–323.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jonsson, M., Walder, M. & Forsgren, A. First clinical isolate of highly fluoroquinolone-resistantEscherichia coli in scandanavia. Eur. J. Clin. Microbiol. Infect. Dis. 9, 851–853 (1990). https://doi.org/10.1007/BF01967392
Issue Date:
DOI: https://doi.org/10.1007/BF01967392